206 results
8-K
EX-10.3
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
"Confidential" or equivalent; (ii) the CervoMed's research and development initiatives, marketing and customer support strategies, financial information … technology, including, but not limited to, discoveries, inventions, research and development efforts, data, software, trade secrets, processes, samples
8-K
EX-99.1
CRVO
CervoMed Inc
15 May 24
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5:06pm
to approximately $1.4 million for the same period in 2023.
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 were approximately
8-K
EX-99.1
473unxy
5 Apr 24
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
gnspu2zl
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-99.1
h5ewv0o9y1bg
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-10.1
cbj5f 82pka
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-99.1
qj6uyu2hywez 8e6
13 Nov 23
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
4:06pm
8-K/A
EX-99.2
1l4pns54tebnd
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
iyq zenx1xmpe3ow
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.1
2l4hbdtwa518mumiu
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K
v7igz
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
425
EX-99.1
thdpi
9 Aug 23
Business combination disclosure
4:02pm
425
EX-99.2
gk6exlhgj1sn0e4 ds
9 Aug 23
Business combination disclosure
4:02pm